QIAGEN opens New Service Solutions Center in Asia
State of the art facility completes global customer care network and supports further expansion in the region
Venlo, The Netherlands / Singapore - February 22, 2008 - QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today opened a new Service Solutions Center in Singapore for the Asia-Pacific region. The facility completes the Company's global Service Solution Network by adding a center in the Asia-Pacific region to its existing centers in the United States (Valencia, CA and Germantown, MD), Europe (Hilden, Crawley, Paris) and Japan (Tokyo). By the end of 2008, QIAGEN's global customer support network will provide comprehensive solutions-oriented service to customers at any time in any place in the world.
The new center will further increase the Company's responsiveness to the information and service requirements of customers in research, applied testing, pharma and molecular diagnostics in the entire Asian-Pacific region including Australia, allowing them to access the Company's services faster, more conveniently and more efficiently. The facility will serve as a base for QIAGEN employees who will handle customer care and technical service requests in regional languages including Korean, Mandarin, Cantonese, Malay and English.
"QIAGEN not only sets standards in the development of innovative sample and assay technologies, but also for delivering outstanding service solutions", said Peer M. Schatz, CEO of QIAGEN who hosted the official opening in Singapore. "With this investment we can better respond to the needs of each and every customer, and we can also extend our services to 24 hours a day, 7 days a week in the near future. It moves us even closer to our customers in all our market segments and helps us extend our global reach and enhance service level in this fast growing region."
"We are pleased that QIAGEN has chosen Singapore for its new Service Solutions Center, just after its recent announcement to set up a molecular diagnostics R&D center here. This reinforces Singapore as an excellent location to effectively engage in the fast growing Asia Pacific healthcare market," said Ms Aw Kah Peng, Assistant Managing Director, Singapore Economic Development Board. "We will continue to invest in translational research capabilities, particularly in the area of diagnostics, to further sharpen Singapore's innovative approach towards biomedical research and affordable healthcare."
The new center complements QIAGEN's recent major initiatives in Singapore. In December 2007, the Company opened DX Assay, a joint venture with Bio*One Capital. DX Assay develops molecular diagnostic tests which impact how diseases are detected and treated. In January 2008, QIAGEN announced that it had been awarded an exclusive contract by the Singapore Ministry of Health to supply sample preparation solutions and molecular test kits for the specific detection of Influenza H5N1 viruses - better known as avian flu. QIAGEN employs more than 50 staff in Singapore.
About QIAGEN Asia
With growth rates of 50 per cent, Asia today is QIAGEN's fastest growing market, with Singapore taking significant market share. The Company's strategic expansion into the region began in 2005. Today QIAGEN maintains 7 Asian offices encompassing locations in China, Korea, Malaysia, Hong Kong and Singapore, with over 370 employees. Including the subsidiary in Japan, they contribute approximately 15 per cent to QIAGEN's overall net sales. In 2006, QIAGEN received the Frost & Sullivan Award for Competitive Strategy Leadership in recognition of its strategic initiatives in the Asia Pacific molecular testing market.
QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. QIAGEN's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. In this press release QIAGEN is using the term molecular diagnostics. The use of this term is in reference to certain countries, such as the United States, limited to products subject to regulatory requirements. Current QIAGEN molecular diagnostics products are 34 EU CE IVD assays, six EU CE IVD sample preparation products, one 510k PAX RNA product, nine China SFDA IVD assays and 98 general purpose reagents. Further information about QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
|Dr. Solveigh Mähler||Dr. Thomas Theuringer|
|Director Investor Relations||Associate Director Public Relations|
|QIAGEN N.V.||QIAGEN GmbH|
|+49 2103 29 11710||+49 2103 29 11826|
|e-mail: email@example.com||e-mail: firstname.lastname@example.org|